arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bio Essence Corp

BIOE
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Bio Essence Corp demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap —
Dividend Yield —
Revenue Growth 206.7% ↘
Op. Margin 35.1% ↘
ROIC 11.2% ↗
FCF / Share $0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.02
info Valuation on last close.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$794.71K
↑ +206.7% —
Net Income Profit after all expenses
$205.37K
— 0.0% —
Operating Margin Operating profit as % of sales
35.1%
↓ -18.5% 96th
FCF / Share Free cash flow per share
$0.00
↑ +112.8% —
Long-Term Debt Long-term obligations
$56.84K
↓ -0.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
98
Returns
18
Financial Health ↓
99
Cash Quality ↓
83

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters